| Document |
Document Title |
|
WO/1992/000010A1 |
Invented is a method of treating human prostatic adenocarcinoma by employing a steroid 5-alpha-reductase inhibiting compound or a combination of steroid 5-alpha-reductase inhibiting compounds.
|
|
WO/1991/019731A1 |
Novel angiostatic $g(D)?4,9(11)�-steroids (I), C�21?-oxygenated steroids (II) and other known steroidal compounds have been found to be useful in treating angiogenesis in mammals who have a need for the same. These steroids are usefu...
|
|
WO/1991/018570A1 |
The progesterone analog ST1435 has now been found to attain therapeutically effective levels upon topical application to the skin. ST1435 can be administered topically either in liquid or semisolid base such as a cream or gel or in a sol...
|
|
WO/1991/016897A1 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine r...
|
|
WO/1991/014700A2 |
A process for preparing novel corticosteroid intermediates of formula (XXX) are disclosed. The process entails contacting a 9alpha-hydroxysteroid of formula (XX) with (A) in step (a) an anhydride, an organic acid and an acid reagent havi...
|
|
WO/1991/005557A1 |
Antigestagens (competitive progesterone antagonists) are suitable for the manufacture of medicaments to treat breast cancers with an increased content of tumour cells in the S phase of the cell cycle, regarded as of high risk.
|
|
WO/1991/004984A1 |
The present invention relates to a novel process for the manufacture of (22 R,S)-16alpha, 17alpha-butylidenedioxy-11beta, 21-dihydroxypregna-1,4-diene-3,20-dione (I) by reacting 11beta, 16alpha, 17alpha, 21-tetrahydroxypregna-1,4-diene-3...
|
|
WO/1991/004030A1 |
Disclosed is a method for enhancing the production of T cell lymphokines, which comprises exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to an appropriate concentration of at least one particular s...
|
|
WO/1991/003245A1 |
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions ar disclosed. The compositions contain a combination of a glucocorticoid and an angios...
|
|
WO/1991/001991A1 |
Introduction of a C-12 substituent and especially a beta C-12 substituent into glucocorticoids improves their usefulness as topical anti-inflammatories by increasing their topical activity relative to their systemic activity, thus reduci...
|
|
WO/1990/015068A1 |
The present invention is a process for conversion of DELTA16-steroids (I), to the corresponding DELTA17(20)-20-silyl ether (III), by reaction with (1) a preformed copper hydride or a metal hydride reducing agent in the presence of a copp...
|
|
WO/1990/012577A2 |
A method of inhibiting hair growth in mammals which comprises the topical administration of a composition comprising an anti-angiogenic effective amount of an angiostatic compound of formula (I). The formula (I) compound is present in an...
|
|
WO/1990/012027A1 |
The invention, which relates to the domain of chemistry and in particular therapeutic chemistry, essentially has as its subject matter b-methyl 19-nor pregna 4,6-dienes 17alpha, and if necessary, 21-alkylates of general formula (I) in wh...
|
|
WO/1990/011290A1 |
The invention concerns a method for the preparation of 3-desoxy-4-ene steroids of the general formula I in which R¿1?, R¿2? and R¿3? are a hydrogen atom or a methyl group, R¿4? is a lower alkyl group, a phenyl group or a free, esteri...
|
|
WO/1990/009394A2 |
The process of the present invention is a process for the preparation of an 11-oxygenated steroid of formula (II) which comprises (1) contacting a 9alpha-halo steroid of formula (I) with a metal selected from the group consisting of tin ...
|
|
WO/1990/008128A1 |
Compounds of formula (I), wherein D represents the dehydrogenated residue of a hydroxyl group-containing drug or the dehydrogenated residue of an NH-acidic group-containing drug; the substituents in the phenyl ring alpha and beta are in ...
|
|
WO/1990/000559A1 |
Androstane derivatives of general formula (I) wherein R1 denotes a hydrogen atom or a methyl group, X and Y each denote a hydrogen atom or together denote a carbon-carbon bond, R2 denotes a hydrogen atom or an alkyl group with 1 to 6 car...
|
|
WO/1990/000174A1 |
The invention concerns 13-Alkyl-11beta-phenylgonanes of general formula (I), wherein Z, R1, R2, R3 and R4 have the meaning given, a process for their preparation, pharmaceutical preparations containing these compounds, and their use for ...
|
|
WO/1989/012448A1 |
An 11beta-aryl-19-norprogesterone steroid of formula (I): wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, ...
|
|
WO/1989/010963A1 |
Genetically engineered host cells containing new expression cassettes are provided which are able to carry out biochemical oxidations of steroids. In particular the oxidation is carried out with cells into which DNA has been introduced w...
|
|
WO/1989/009781A1 |
New 9alpha-hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9alpha-hydroxyandrost-4-ene-3,17-dione. The resulting compounds are useful starting compounds in the synthesis of corticoste...
|
|
WO/1989/006231A1 |
This invention concerns chemiluminescent moieties useful as labels in assays and immunoassays, and compositions and assay kits incorporating the moieties. The chemiluminescent moieties are of the type wherein attack by peroxide or molecu...
|
|
WO/1989/002272A1 |
A method of using 3-hydroxylated-5-reduced steroids and certain novel derivatives which act at a newly identified site on the GBR complex, to modulate brain excitability in a manner which will alleviate stress, anxiety, and seizure activ...
|
|
WO/1989/001483A1 |
The invention involves a two-step chemical transformation of a steroidal 17-cyanohydrin of formula (II) to a 17alpha-hydroxy-21-halo-20-keto steroid of formula (IV) intermediate which can readily be converted to pharmaceutically useful c...
|
|
WO/1989/001327A1 |
A composition based on hydrated lipidic lamellar phases or liposomes is characterized in that said phases or said liposomes contain, at least in part, pregnenolone or a pregnenolone ester, in particular pregnenolone acetate, sulphate or ...
|
|
WO/1989/001482A1 |
The present invention involves improved processes for the dehalogenation of 9alpha-halosteroids (I), to produce the corresponding 11beta-hydroxy steroids (II), which are known to be useful as pharmaceutical, where the improvements compri...
|
|
WO/1989/000558A1 |
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 - + HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is C1-C...
|
|
WO/1988/009337A1 |
This invention concerns a method of substituting a chlorine atom for a predetermined hydrogen atom located within an organic compound which comprises contacting the organic compound containing the predetermined hydrogen atom with an este...
|
|
WO/1988/007092A1 |
The present invention involves processes for 1,2-dehydrogenation of DELTA4-3-keto C21-hemiester steroids of formula (I), with Arthrobacter simplex or Bacterium cyclooxydans to produce the corresponding DELTA1,4-3-keto C21 hemiester of fo...
|
|
WO/1988/003534A1 |
17beta-Cyano-17alpha-hydroxy steroids (I) are transformed to 17alpha-halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoids (III...
|
|
WO/1988/002753A2 |
New 9-alpha-hydroxy steroids are prepared by the introduction of substituents on the D-ring of 9-alpha-hydroxy-androst-4-ene-3,17-dione. The resulting compounds are useful intermediates in the synthesis of corticosteroids.
|
|
WO/1987/007895A1 |
Androstane-type aminoesters (IV) and cortical aminoesters (VIII), more particularly 17-aminoesters (I), 11,17-diaminoesters (II), 3,17-diaminoesters (III), 21-aminoesters (V), 11-aminoesters (VI), and 3-aminoesters (VII) which are useful...
|
|
WO/1987/007612A1 |
Process for the production of a DELTA17(20)-steroid of formula (II) which comprises starting with a 16-unsaturated corticoid of formula (I) and contacting the 16-unsaturated corticoid (I) with a methylating agent in the presence of a cop...
|
|
WO/1987/005028A1 |
Compounds of formula (I), wherein one X is COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; remaining X's are H, F, CH3, OH, COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; Y is (i1), (i2), (i3), (i4), or (i5); R is H, alkyl of 1-5 ca...
|
|
WO/1987/002672A1 |
Novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of formula (I), wherein R15 is = O or -OH; wherein R23 with R10 forms a cyclic phosphate of formula (II) or wherein R23 is...
|
|
WO/1987/001706A2 |
Disclosed are DELTA9(11)-steroids (VI) and amino substituted steroids of formula (XI), which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroi...
|
|
WO/1986/003750A1 |
A method for preparing a stable aerosol formulation of beclomethasone dipropionate in which the steroid is contacted with an alcohol containing 1 to 5 carbon atoms to form a crystalline solvate therewith, the crystalline material so form...
|
|
WO/1986/000907A1 |
A process for the manufacture of 6alpha-methyl steroids having general formula (I) in which X is a hydroxy group and Y a hydrogen atom, or X and Y are together a carbon-carbon bond and R1 is a cyano group, an acetyl group or an alkanoylo...
|
|
JP7438956B2 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
JP7437384B2 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are meth...
|
|
JP2023524494A |
Described herein are processable compositions comprising at least one moiety that is processable in free form. Also used herein are glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior ocular inflammation, anteri...
|
|
JP2023521886A |
The present invention relates to methods and reagents for determining the presence or amount of an analyte in a sample.
|
|
JP2023071910A |
To provide pharmaceuticals that are neuroactive and suitable for use as an anesthetic.The present invention is generally directed to neuroactive 19-alkoxy-17-substituted steroids with the structure in the figure and pharmaceutically acce...
|
|
JP2023514299A |
The present invention relates to compounds for the treatment of gout, their method of preparation and use. Such compounds are those of Formula I. The present invention discloses methods of making said compounds and the use of said compou...
|
|
JP7241792B2 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
JP2022188127A |
To provide aseptic suspensions, physically stable and injectable through a 25-G or thinner needle, and methods for manufacturing the same.The present invention relates to: aseptic suspensions, physically stable and injectable through a 2...
|
|
JP2022130546A |
To provide novel neuroactive steroid compounds useful for treatment of central nerve-related diseases.Provided herein are 3,3-disubstituted 19-nor-steroidal compounds represented by Formula (I) in the figure. (R1 is H, Br, OH, heterocycl...
|
|
JP2022538300A |
As used herein, compounds of formula (1-I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided herein a...
|
|
JP7106773B1 |
To provide a method for efficiently producing steroids 17α, 21-diesters such as betamethasone butyrate propionic acid ester and dexamethasone propionic acid ester. DMF (N, N-dimethylformamide) is added to betamethasone or dexamethasone,...
|
|
JP7096864B2 |
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I):where R1, R2, R3, R3', R4, R6a, R6a, R11a, and R11bare as defined herein. Compounds of the present invention are contemplated useful for the preven...
|
